Can-Fite BioPharma's market cap is currently ―. The company's EPS TTM is $-1.857; its P/E ratio is -1.06; Can-Fite BioPharma is scheduled to report earnings on May 30, 2024, and the estimated EPS forecast is $-0.40. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Sep 22	Jun 22	Mar 22
Income Statement	-
Total Revenue	-	-	$ 204.00K	$ 204.00K	$ 205.00K
Gross Profit	-	-	-	-	-
EBIT	-	-	$ -2.57M	$ -2.07M	$ -2.37M
EBITDA	-	-	$ -2.57M	$ -2.07M	$ -2.37M
Net Income Common Stockholders	-	-	$ -2.53M	$ -2.19M	$ -2.43M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 8.92M	$ 7.99M	$ 10.81M	$ 12.77M	$ 16.70M
Total Assets	$ 9.99M	$ 9.28M	$ 12.71M	$ 14.75M	$ 17.85M
Total Debt	$ 40.00K	$ 62.00K	$ 74.00K	$ 87.00K	$ 109.00K
Net Debt	$ -8.88M	$ -7.92M	$ -10.74M	$ -12.68M	$ -16.59M
Total Liabilities	$ 3.75M	$ 4.81M	$ 5.28M	$ 4.85M	$ 5.82M
Stockholders Equity	$ 6.24M	$ 4.47M	$ 7.43M	$ 9.89M	$ 12.02M
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in USD

Can-Fite BioPharma Earnings and Revenue History

Income Statement >

Can-Fite BioPharma Debt to Assets

Balance Sheet >

Can-Fite BioPharma Cash Flow

Cash Flow >

Can-Fite BioPharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing